• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . SARS-CoV-2 seroprevalence in Barcelona and Catalonia (Spain) after the 2020 lockdown

tetano

Editor, Senior Moderator
Sci Rep


. 2026 Jun 23.
doi: 10.1038/s41598-026-58310-7. Online ahead of print.
SARS-CoV-2 seroprevalence in Barcelona and Catalonia (Spain) after the 2020 lockdown

Candela Fernández-Naval[SUP] 1 [/SUP], Aroa Silgado[SUP] 2 3 [/SUP], Albert Blanco-Grau[SUP] 4 5 [/SUP], Eva Dopico[SUP] 6 [/SUP], Laura Calatayud[SUP] 6 [/SUP], Gema Fernández-Rivas[SUP] 7 8 [/SUP], Aroa Muñoz Quinto[SUP] 7 [/SUP], Maria Teresa Sans-Mateu[SUP] 9 [/SUP], Frederic F Gómez-Bertomeu[SUP] 10 [/SUP], Dúnia Perez Del Campo[SUP] 11 [/SUP], Mercè Montesinos-Costa[SUP] 11 [/SUP], Albert Bernet[SUP] 12 [/SUP], Alba Bellés[SUP] 12 [/SUP], Imma Comas[SUP] 4 5 [/SUP], Susana Otero-Romero[SUP] 13 [/SUP], Rosa María Moreno Ródenas[SUP] 1 [/SUP], Nieves Larrosa[SUP] 1 3 [/SUP], Andrés Antón[SUP] 1 3 [/SUP], Juliana Esperalba[SUP] 14 15 [/SUP]


Affiliations
Free article Abstract

The study aimed to assess seroprevalence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Barcelona city (SRCOV2-BCN study) and the region of Catalonia, Spain (SRCOV2-CAT study) prior to the availability of coronavirus (COVID-19) vaccines. Humoral response to SARS-CoV-2 infection was assessed by detection of total antibodies (IgG, IgA and IgM) in surplus specimens from routine blood draw in the biochemistry laboratories of the participant hospitals. In Barcelona city, SARS-CoV-2 seroprevalence was 10.2% both in April and July 2020, without differences between men and women. The highest seroprevalence was found in individuals between 50 and 64 years old (13.7%). In Catalonia, SARS-CoV-2 seroprevalence in July 2020 was 9.2% and it was higher in women (10.1%) than in men (7.5%) (P = 0.0066), especially in the 50-64 age group (12.7% in women vs. 5.4% in men, P = 0.00051). The highest prevalence by age groups was 10%, found in individuals between 35 and 64 years old. Seroprevalence in the Barcelona province (11.7%) was higher than in the other provinces. In conclusion, SAR-CoV-2 seroprevalence in Catalonia during the first months of COVID pandemics was moderately high. There were differences by age, sex and geographical location that should be investigated.

Keywords: COVID-19; Leftover blood samples; Primary care; SARS-CoV-2; Seroprevalence; Vaccine

 
Back
Top